Cargando…

Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives

Cabozantinib (Cabometyx(®)) is a potent multikinase inhibitor targeting the vascular endothelial growth factor (VEGF) receptor 2, the mesenchymal-epithelial transition factor (MET) receptor, and the “anexelekto” (AXL) receptor tyrosine kinase. It is approved for the treatment of advanced hepatocellu...

Descripción completa

Detalles Bibliográficos
Autor principal:	Trojan, Jörg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395054/ https://www.ncbi.nlm.nih.gov/pubmed/32671719 http://dx.doi.org/10.1007/s40265-020-01361-5

Ejemplares similares

The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges
por: D’Alessio, Antonio, et al.
Publicado: (2021)

Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
por: Rathi, Nityam, et al.
Publicado: (2020)

Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma
por: Storandt, Michael H., et al.
Publicado: (2022)

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
por: Kelley, Robin K., et al.
Publicado: (2020)

Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
por: Hsu, Chih-Hung, et al.
Publicado: (2014)

Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations
por: Debaillon Vesque, Audrey, et al.
Publicado: (2020)

Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma
por: Schwartz, Gabriel, et al.
Publicado: (2020)

Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma
por: Shang, Runze, et al.
Publicado: (2021)

Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
por: Trojan, Jörg, et al.
Publicado: (2016)

Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis
por: Shlomai, Amir, et al.
Publicado: (2019)

An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives
por: Iaxx, Romain, et al.
Publicado: (2022)

Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade
por: Kelley, Robin Kate, et al.
Publicado: (2021)

Biomarkers in Hepatocellular Carcinoma: Current Status and Future Perspectives
por: Pan, Yasi, et al.
Publicado: (2020)

Immunotherapy for hepatocellular carcinoma: current status and future perspectives
por: Okusaka, Takuji, et al.
Publicado: (2018)

Current status and future perspectives of radiomics in hepatocellular carcinoma
por: Miranda, Joao, et al.
Publicado: (2023)

EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma
por: Ma, Xuhui, et al.
Publicado: (2022)

Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study
por: Kudo, Masatoshi, et al.
Publicado: (2021)

Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives
por: Rinninella, Emanuele, et al.
Publicado: (2017)

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
por: Grassi, Paolo, et al.
Publicado: (2016)

Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations
por: Xie, Yingjun, et al.
Publicado: (2018)

The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
por: Wong, Jeffrey Sum-Lung, et al.
Publicado: (2021)

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
por: Bersanelli, Melissa, et al.
Publicado: (2018)

Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer
por: Hart, Christopher D, et al.
Publicado: (2013)

Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity
por: Ho, Won Jin, et al.
Publicado: (2021)

Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives
por: Girardi, Daniel M., et al.
Publicado: (2023)

Development of cabozantinib for the treatment of prostate cancer
por: Vaishampayan, Ulka N
Publicado: (2014)

Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison
por: Trojan, Jörg, et al.
Publicado: (2021)

Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives
por: Lu, Li-Chun, et al.
Publicado: (2019)

Systemic treatments for hepatocellular carcinoma: challenges and future perspectives
por: Tovoli, Francesco, et al.
Publicado: (2018)

Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
por: Zhang, Shuming, et al.
Publicado: (2023)

Clinical Utility of Cabozantinib in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Carcinoma: Patient Selection and Reported Outcomes
por: Roof, Logan, et al.
Publicado: (2023)

Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States
por: Sieg, Maximilian, et al.
Publicado: (2020)

Impact of Cabozantinib Exposure on Proteinuria and Muscle Toxicity in Patients with Unresectable Hepatocellular Carcinoma
por: Okubo, Hironao, et al.
Publicado: (2022)

Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
por: Kelley, Robin Kate, et al.
Publicado: (2020)

The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma
por: Montella, Liliana, et al.
Publicado: (2021)

Immunotherapy for hepatocellular carcinoma: Current and future
por: Johnston, Michael P, et al.
Publicado: (2019)

Immunotherapy for hepatocellular carcinoma: Current status and future perspectives
por: Mandlik, Deepa S, et al.
Publicado: (2023)

Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis
por: Bang, Yeong Hak, et al.
Publicado: (2022)

Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
por: Zhang, Shuming, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iavefkmr8fpb717nttg69iulhd